Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors [Yahoo! Finance]
PLUS THERAPEUTICS, Inc. (PSTV)
Company Research
Source: Yahoo! Finance
healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of diagnostics industry veteran Ron Andrews to its Board of Directors. “Ron Andrews brings an extensive wealth of diagnostics experience to the Plus board room developed over multiple decades in the industry,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “He will make an immediate impact on the Company as we scale CNSide, first in the U.S. and then globally. Furthermore, his breadth of connections throughout the global diagnostics industry will help the Company maximize the positive impact of CNSide on patients with central nervous system cancers and drive value for stockholders.” Mr. Andrews currently is an experienced leader in the Diagnostics and Molecular Diagnostics industry with over 35 years leading various sized organizations from divisions of large global entities such a
Show less
Read more
Impact Snapshot
Event Time:
PSTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSTV alerts
High impacting PLUS THERAPEUTICS, Inc. news events
Weekly update
A roundup of the hottest topics
PSTV
News
- Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of DirectorsGlobeNewswire
- Plus Therapeutics (PSTV) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $3.00 price target on the stock.MarketBeat
- Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%GlobeNewswire
- Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout [Yahoo! Finance]Yahoo! Finance
- Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial RolloutGlobeNewswire
PSTV
Earnings
- 8/14/25 - Beat
PSTV
Sec Filings
- 3/26/26 - Form 8-K
- 3/12/26 - Form 8-K
- 3/12/26 - Form 10-K
- PSTV's page on the SEC website